CLAIM #40834 · Medtronic PLC (MDT) · 2026Q3 earnings call · Feb 17, 2026 · due Apr 30, 2027
“Look, first, it's a little bit less than 2 points of full growth. And again, we'll give you the specific calculations as we close the year, but the way to think of it is that there's going to be growth acceleration, excluding the extra week, right? So it should be upside.”
Thierry Pieton · CFO
How to check this claim
Look at: Organic revenue growth rate for fiscal year 2027, excluding the extra week contribution
It came true if: FY2027 organic growth (ex-extra week) higher than FY2026 organic growth rate
Where: Company-reported organic revenue growth disclosure (10-K/earnings release/call commentary)
In context
“ves, like for Ardian. We're already up to like 100 million covered lives. It's about 1/3 of the population here in the U.S. So those are all leading indicators, and we'll start putting more other, as you put, goalpost out there as this starts to mature a little bit, both of these launches. I don't know if you have anything to add to that, Thierry? Thierry Pieton: No. Vijay Kumar: Great. And just 1 clarification on the extra week Geoff, we're looking at exit rates of 6% organic, right? And let's assume next year is north of 6%. The extra week is almost 2 points of growth. So are we looking at base organic excluding extra week somewhere in the 5%-ish range or any thoughts on how to think about extra week contribution? Thierry Pieton: So maybe I'll take that one, and thanks for the question. Look, first, it's a little bit less than 2 points of full growth. And again, we'll give you the specific calculations as we close the year, but the way to think of it is that there's going to be growth acceleration, excluding the extra week, right? So it should be upside. So we should have better growth than we have in fiscal year '26, in '27 and the extra week should be on top of that. Geoffrey Martha: that clear, Vijay? Vijay Kumar: Crystal clear, yes. Operator: And our next question comes from Larry Biegelsen at Wells Fargo. Larry Biegelsen: Geoff, I wanted to ask about cash and your growth continued to accelerate this quarter to 80% worldwide, which implies the worldwide EP market grew about 20% in calendar year Q4. So my question is, how are you thinking about the EP market growth in calendar year '26, and your CAS growth going forward now that you're lapping the Affera U.S. launch? I think to achieve the trailing 12-month $2 billion goal, it looks like your CAS growth has to kind of sustain about 80% in the next 2 quarters. Is that directionally accu”
Verify independently
SEC filings for MDT ↗ · Claim quote is verbatim from the 2026Q3 earnings call.